Khurana And Khurana (K&K) Advises Medikabazaar On Its Series C Funding

Khurana and Khurana acted as the IP Counsel for Medikabazaar on its recent funding round where the Company, a leading B2B health-tech entity, raised $75 million in its Series C funding round that was led by CREAEGIS along with CDC Group. K&K advised Medikabazaar on IP Law issues during its highest fundraising in the B2B healthcare space. Reportedly, following the completion of funding, valuation of the company soared to $260 million, aiming at 300% growth through FY22. Existing Investors who participated include Belgium-based Ackermans & van Haaren (AvH), HealthQuad Advisors Private Limited, Japan-based Rebright Partners, Continental Europe-based Kois Holdings, and Sumitomo Mitsui Financial Group. Subject to the regulations, Medikabazaar will use the fund for its digital capabilities; deepen the supply ecosystem & technology-driven distribution channel. Previously, Medikabazaar has raised $15.8 million in its Series B funding in 2019. The advisory team from K&K included Tarun Khurana and Abhijeet Deshmukh.